Scientists at Albert Einstein College of Medicine have discovered the first compound that directly makes cancer cells commit suicide while sparing healthy cells. The new treatment approach, described in today’s issue of Cancer Cell, was directed against acute myeloid leukemia (AML) cells but may also have potential for attacking other types of cancers.
“We’re hopeful that the targeted compounds we’re developing will prove more effective than current anti-cancer therapies by directly causing cancer cells to self-destruct,” says Evripidis Gavathiotis, Ph.D., associate professor of biochemistry and of medicine and senior author of the study. “Ideally, our compounds would be combined with other treatments to kill cancer cells faster and more efficiently—and with fewer adverse effects, which are an all-too-common problem with standard chemotherapies.”
AML accounts for nearly one-third of all new leukemia cases and kills more than 10,000 Americans each year. The survival rate for patients has remained at about 30 percent for several decades, so better treatments are urgently needed.
The newly discovered compound combats cancer by triggering apoptosis—an important process that rids the body of unwanted or malfunctioning cells. Apoptosis trims excess tissue during embryonic development, for example, and some chemotherapy drugs indirectly induce apoptosis by damaging DNA in cancer cells.
Apoptosis occurs when BAX—the “executioner protein” in cells—is activated by “pro-apoptotic” proteins in the cell. Once activated, BAX molecules home in on and punch lethal holes in mitochondria, the parts of cells that produce energy. But all too often, cancer cells manage to prevent BAX from killing them. They ensure their survival by producing copious amounts of “anti-apoptotic” proteins that suppress BAX and the proteins that activate it.
“Our novel compound revives suppressed BAX molecules in cancer cells by binding with high affinity to BAX’s activation site,” says Dr. Gavathiotis. “BAX can then swing into action, killing cancer cells while leaving healthy cells unscathed.”
Dr. Gavathiotis was the lead author of a 2008 paper in Nature that first described the structure and shape of BAX’s activation site. He has since looked for small molecules that can activate BAX strongly enough to overcome cancer cells’ resistance to apoptosis. His team initially used computers to screen more than one million compounds to reveal those with BAX-binding potential. The most promising 500 compounds—many of them newly synthesized by Dr. Gavathiotis’ team—were then evaluated in the laboratory.
“A compound dubbed BTSA1 (short for BAX Trigger Site Activator 1) proved to be the most potent BAX activator, causing rapid and extensive apoptosis when added to several different human AML cell lines,” says lead author Denis Reyna, M.S., a doctoral student in Dr. Gavathiotis’ lab. The researchers next tested BTSA1 in blood samples from patients with high-risk AML. Strikingly, BTSA1 induced apoptosis in the patients’ AML cells but did not affect patients’ healthy blood-forming stem cells.
Finally, the researchers generated animal models of AML by grafting human AML cells into mice. BTSA1 was given to half the AML mice while the other half served as controls. On average, the BTSA1-treated mice survived significantly longer (55 days) than the control mice (40 days), with 43 percent of BTSA1-treated AML mice alive after 60 days and showing no signs of AML.
Importantly, the mice treated with BTSA1 showed no evidence of toxicity. “BTSA1 activates BAX and causes apoptosis in AML cells while sparing healthy cells and tissues—probably because the cancer cells are primed for apoptosis,” says Dr. Gavathiotis. He notes that his study found that AML cells from patients contained significantly higher BAX levels compared with normal blood cells from healthy people. “With more BAX available in AML cells,” he explained, “even low BTSA1 doses will trigger enough BAX activation to cause apoptotic death, while sparing healthy cells that contain low levels of BAX or none at all.”
Plans call for Dr. Gavathiotis and his team to see whether BTSA1 will show similar effectiveness when tested on animal models of other types of cancer.
The Latest on: Cancer cells commit suicide
- Legend Loston June 22, 2020 at 10:06 pm
The Williamsville resident passed away Monday after a lengthy cancer battle. He was 79 ... His daughter, Christine, committed suicide in 1993. She was 24. “The pain stays with you for years,” ...
- GSK strikes $170m-plus ‘synthetic lethality’ cancer deal with Ideayaon June 17, 2020 at 4:21 am
GlaxoSmithKline has made another push back into cancer R&D via a licensing deal with US biotech Ideaya focusing on ‘synthetic lethality’ – an approach that aims to force cancer cells to commit suicide ...
- Postdoc Jobs at URMCon June 15, 2020 at 5:00 pm
It will employ single cell sequencing and bioinformatics ... three years of stipend support and related benefits for early career investigators committed to careers in suicide prevention research.
- CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cellson June 10, 2020 at 5:00 pm
and order a cell to commit suicide when something goes wrong. When p53 is not working, tumors can grow. Researchers reported in the Nature Medicine papers that dysfunctional p53 activity might be ...
- Healios Successfully Establishes Proprietary Universal Donor Cell Research Lineon June 5, 2020 at 2:00 am
Healios plans to combine its UDC technology with its existing efforts in next-generation cancer-targeting immune ... and the addition of a suicide gene serving as a safety mechanism, each in an ...
- Healios Successfully Establishes Proprietary Universal Donor Cell Research Lineon June 4, 2020 at 10:30 pm
Healios plans to combine its UDC technology with its existing efforts in next-generation cancer ... of a suicide gene serving as a safety mechanism, each in an allogeneic iPS cell.
- Healios Successfully Establishes Proprietary Universal Donor Cell Research Lineon June 4, 2020 at 10:10 pm
Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are next-generation iPS cells created with gene-editing technology to engineer a low risk of ...
- Cyclacel Looks to ASCO as Showcase for Potent Cancer-Fighting Cocktailon May 30, 2020 at 5:00 pm
Cyclacel was founded on the hope of developing compounds that could control “cell cycle regulation”—essentially by inducing cancer cells to commit suicide, while sparing the normal cells ...
via Google News and Bing News